4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 99 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q4 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $156 | +44.4% | 12,254 | +95.3% | 0.00% | +100.0% |
| Q1 2023 | $108 | -43.8% | 6,275 | -27.3% | 0.00% | -50.0% |
| Q4 2022 | $192 | -99.9% | 8,631 | -59.4% | 0.00% | 0.0% |
| Q3 2022 | $171,000 | +59.8% | 21,237 | +38.7% | 0.00% | +100.0% |
| Q2 2022 | $107,000 | -15.1% | 15,309 | +83.5% | 0.00% | 0.0% |
| Q1 2022 | $126,000 | -40.6% | 8,342 | -13.8% | 0.00% | 0.0% |
| Q4 2021 | $212,000 | -44.6% | 9,680 | -31.8% | 0.00% | -50.0% |
| Q3 2021 | $383,000 | +71.7% | 14,197 | +53.2% | 0.00% | +100.0% |
| Q2 2021 | $223,000 | -84.0% | 9,265 | -72.5% | 0.00% | -85.7% |
| Q4 2020 | $1,396,000 | – | 33,680 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,007,413 | $68,887,429 | 2.52% |
| Opaleye Management Inc. | 314,000 | $5,397,660 | 1.62% |
| Deep Track Capital, LP | 2,278,107 | $39,160,659 | 1.61% |
| Casdin Capital, LLC | 1,070,000 | $18,393,300 | 1.52% |
| Eagle Health Investments LP | 437,911 | $7,527,690 | 1.46% |
| ACUTA CAPITAL PARTNERS, LLC | 104,753 | $1,800,704 | 1.33% |
| Octagon Capital Advisors LP | 499,996 | $8,594,931 | 1.24% |
| Soleus Capital Management, L.P. | 469,400 | $8,068,986 | 0.84% |
| Novo Holdings A/S | 700,000 | $12,033,000 | 0.79% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $67,692,742 | 0.32% |